Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258321 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
A Phase 1 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02258321 is a Phase 1 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT02258321, a Phase 1 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.
Interventions
- DRUG PPI-668 capsule
- DRUG PPI-668 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02258321
The ClinicalTrials.gov registry entry for NCT02258321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presidio Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PPI-668 capsule is the first listed.
NCT02258321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02258321 about?
NCT02258321 is a clinical study titled "Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations". This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet, T003.
What is the current status of trial NCT02258321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02258321?
The interventions under investigation include: PPI-668 capsule (DRUG), PPI-668 tablet (DRUG).
Who is sponsoring clinical trial NCT02258321?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.